Netherlands Cancer Institute transitioning to Proscia digital pathology platform

By Author Proscia | January 18, 2023

NKI, an early adopter of digital pathology, selected the enterprise-grade Concentriq Dx* to serve as the modern platform at the center of its growing oncology practice.

*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.

Our website uses cookies. By using this site, you agree to its use of cookies.